EGFR and non-small cell lung carcinoma: EGFR‐TKIs are the standard treatment for EGFR mutation‐positive advanced NSCLC.2, 3, 4, 5, 6, 7 The ORR and median PFS in patients treated with a first‐ or second‐generation EGFR‐TKI as first‐line treatment have been reported to be 56%–74% and 9.2–13.1 months, respectively.2, 3, 4, 5, 6, 7, 16, 17 Although these patients showed excellent responses to first‐ and second‐generation EGFR‐TKIs and improved prognosis, almost all patients had become resistant to treatment over time.